NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Continue.

Remember, the easy tumors to remove are not the ones DCVax-l works best on. Instead, mesenchymal tumors are more infiltrative and tend to jut out in various places. This is probably why you still see many partial resections in the DCVax-l trial. — flipper

And that’s in part confirmed in my opinion, by the NYAS DCVax slide deck, because DCVax-l was statistically significant in significant residual disease cases,and that translated into, uncharacteristically (but logically), not only better long term survival than the external control arm at five years, but DCVax-l treating significant residual disease exceeded exceeded five year survival of DCVax-l treating minimal residual disease. 🔑🔑🔑